BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33677616)

  • 61. Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.
    Tuffaha HW; Al Omar S
    J Oncol Pharm Pract; 2011 Jun; 17(2):136-40. PubMed ID: 19833686
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
    Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
    J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
    [TBL] [Abstract][Full Text] [Related]  

  • 63. High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines.
    Diddens H; Teufel T; Niethammer D
    Cancer Chemother Pharmacol; 1987; 20(2):128-32. PubMed ID: 3499251
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The inability of oral leucovorin to elevate CSF 5-methyl-tetrahydrofolate following high dose intravenous methotrexate therapy.
    Allen J; Rosen G; Juergens H; Mehta B
    J Neurooncol; 1983; 1(1):39-44. PubMed ID: 6611387
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Optimal management of methotrexate intoxication in a child with osteosarcoma.
    Peyriere H; Cociglio M; Margueritte G; Vallat C; Blayac JP; Hillaire-Buys D
    Ann Pharmacother; 2004 Mar; 38(3):422-7. PubMed ID: 14970366
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities.
    Foster JH; Thompson PA; Bernhardt MB; Margolin JF; Hilsenbeck SG; Jo E; Marquez-Do DA; Scheurer ME; Schafer ES
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):349-360. PubMed ID: 30488179
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Toxicity of high dose methotrexate repeated infusions in children treated for acute lymphoblastic leukemia and osteosarcoma].
    Ridolfi L; Barisone E; Vivalda M; Vivenza C; Brach Del Prever A; Leone L; Miniero R
    Minerva Pediatr; 1996 May; 48(5):193-200. PubMed ID: 8926955
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Understanding and managing methotrexate nephrotoxicity.
    Widemann BC; Adamson PC
    Oncologist; 2006 Jun; 11(6):694-703. PubMed ID: 16794248
    [TBL] [Abstract][Full Text] [Related]  

  • 69. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy.
    Dupuis C; Mercier C; Yang C; Monjanel-Mouterde S; Ciccolini J; Fanciullino R; Pourroy B; Deville JL; Duffaud F; Bagarry-Liegey D; Durand A; Iliadis A; Favre R
    Anticancer Drugs; 2008 Mar; 19(3):267-73. PubMed ID: 18510172
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure.
    Buchen S; Ngampolo D; Melton RG; Hasan C; Zoubek A; Henze G; Bode U; Fleischhack G
    Br J Cancer; 2005 Feb; 92(3):480-7. PubMed ID: 15668713
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High-dose methotrexate with a safe rescue program.
    Decker DA; Edmonson JH; Gilchrist GS; Kovach JS; Offord JR; Taylor WF
    Oncology; 1981; 38(5):262-4. PubMed ID: 6973732
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma].
    Graf N; Jost W; Müller J; Keller HE; Sitzmann FC
    Klin Padiatr; 1990; 202(5):340-6. PubMed ID: 2214594
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
    Winter SS; Dunsmore KP; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Gaynon PS; Borowitz MJ; Loh ML; Rabin KR; Raetz EA; Zweidler-Mckay PA; Winick NJ; Carroll WL; Hunger SP
    J Clin Oncol; 2018 Oct; 36(29):2926-2934. PubMed ID: 30138085
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
    Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
    Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
    Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Reversible Impaired Methotrexate Clearance After Platinum-Based Chemotherapy for Osteosarcoma.
    Oude Munnink T; van der Meer A; de Haan J; Touw D; van Kruchten M
    Ther Drug Monit; 2019 Dec; 41(6):693-695. PubMed ID: 31169759
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Correlation study of blood drug concentration and nephrotoxicity on high dose methotrexate therapy in suggestion of diagnosis and treatment of childhood acute lymphoblastic leukemia in the 4th revised edition].
    Cheng DH; Lu H; Zou XQ
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):771-774. PubMed ID: 29050116
    [No Abstract]   [Full Text] [Related]  

  • 79. Epidemiologic Characteristics of Acute Kidney Injury During Cisplatin Infusions in Children Treated for Cancer.
    McMahon KR; Rassekh SR; Schultz KR; Blydt-Hansen T; Cuvelier GDE; Mammen C; Pinsk M; Carleton BC; Tsuyuki RT; Ross CJD; Palijan A; Huynh L; Yordanova M; Crépeau-Hubert F; Wang S; Boyko D; Zappitelli M;
    JAMA Netw Open; 2020 May; 3(5):e203639. PubMed ID: 32383745
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Time evolution of methotrexate-induced kidney injury: A comparative study between different biomarkers of renal damage in rats.
    Severin MJ; Campagno RV; Brandoni A; Torres AM
    Clin Exp Pharmacol Physiol; 2019 Sep; 46(9):828-836. PubMed ID: 31187885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.